This study is for people with geographic atrophy (GA), a condition where cells in the retina die, leading to vision loss. GA is an advanced stage of age-related macular degeneration (AMD), which damages the macula, a key part of the eye. The study focuses on the use of avacincaptad pegol, a treatment approved in the US to slow GA progression. It's an observational study, meaning it collects information from medical records without altering treatment.

Participants will have regular eye exams and complete surveys about their eye health. Surveys occur at treatment start, every 6 months for 2 years, then yearly. The study lasts up to 3-5 years, depending on when participants join. Treatment decisions are made by the participant's doctor, not the study's sponsor, Astellas.

• Participation requires regular eye exams and surveys.
• The study spans 3 to 5 years.
• Doctor's decision is crucial for participation.